BioCentury | Jun 29, 2019
Finance

All eyes on new modality launches, cancer and rare disease data in 3Q19

...refractory aggressive large B cell non-Hodgkin’s lymphoma (NHL) Submit BLA 2H19 Celsion Corp. (NASDAQ:CLSN) / Yakult Honsha Co. Ltd....
BioCentury | May 9, 2018
Distillery Therapeutics

Cancer

...includes Phase I testing of AZD0156 in combination with Camptosar or Lynparza in solid tumors. Yakult Honsha Co. Ltd....
BioCentury | Dec 15, 2017
Clinical News

4SC reports Phase I data for resminostat in pancreatic and biliary tract cancer

...In September, 4SC AG (Xetra:VSC) said partner Yakult Honsha Co. Ltd. (Tokyo:2267) reported data from a Phase I trial...
...Data were presented at the European Society for Medical Oncology meeting in Madrid. 4SC said Yakult...
...Drug designation in the U.S. and EU to treat Hodgkin's lymphoma and hepatocellular cancer (HCC). Yakult...
BioCentury | Dec 7, 2016
Clinical News

ThermoDox: Ph III OPTIMA ongoing

...RFA) vs. RFA alone. The trial has enrolled about 40% of the planned 550 patients. Yakult...
...in 2013 (see BioCentury, Jan. 28, 2013 ). Celsion Corp. (NASDAQ:CLSN; Tel Aviv:CLSN), Lawrenceville, N.J. Yakult Honsha Co. Ltd....
...PFS) Status: Phase III ongoing Milestone: Complete Phase III enrollment (early 2018) Julian Zhu ThermoDox heat-activated liposome Celsion Corp. Yakult Honsha Co. Ltd. Zhejiang...
BioCentury | Oct 17, 2016
Product Development

Yes we PanCAN

...Pharmaceuticals Inc. (NYSE-M:RNN) RX-3117 DNA methyltransferase Ph I/II 4SC AG (Xetra:VSC) / Menarini Group / Yakult Honsha Co. Ltd....
BioCentury | Sep 29, 2016
Distillery Therapeutics

Therapeutics: Nuclear receptor binding protein 2 (NRBP2)

...adjuvant therapy for HCC. Aeterna Zentaris Inc. , Handok Inc. , Hikma Pharmaceuticals plc and Yakult Honsha Co. Ltd....
BioCentury | Dec 7, 2015
Clinical News

Elplat oxaliplatin regulatory update

...colorectal cancer; as postoperative adjuvant chemotherapy for colon cancer; and for curatively unresectable pancreatic carcinoma. Yakult...
...with oxalate and diaminocyclohexane in Japan under a 1997 deal. Debiopharm Group , Lausanne, Switzerland Yakult Honsha Co. Ltd....
BioCentury | Aug 17, 2015
Clinical News

ThermoDox heat-activated liposome: Additional Phase III data

...& June 24, 2013). ThermoDox is in the Phase III OPTIMA trial to treat HCC. Yakult...
...in China and its territories (see BioCentury, Jan. 28, 2013). Celsion Corp. (NASDAQ:CLSN), Lawrenceville, N.J. Yakult Honsha Co. Ltd....
BioCentury | Aug 10, 2015
Clinical News

Resminostat: Phase I started

...24 patients. The second part will test the selected regimen in an additional 20 patients. Yakult...
...Taiho Pharmaceutical Co. Ltd. (Tokyo, Japan) markets Teysuno in Japan. 4SC AG (Xetra:VSC), Planegg-Martinsried, Germany Yakult Honsha Co. Ltd....
BioCentury | Jul 20, 2015
Clinical News

ThermoDox heat-activated liposome: Updated Phase I/II data

...start the European Euro-DIGNITY trial of ThermoDox in patients with recurrent chest wall breast cancer. Yakult...
...in China and its territories (see BioCentury, Jan. 28, 2013). Celsion Corp. (NASDAQ:CLSN), Lawrenceville, N.J. Yakult Honsha Co. Ltd....
Items per page:
1 - 10 of 109
BioCentury | Jun 29, 2019
Finance

All eyes on new modality launches, cancer and rare disease data in 3Q19

...refractory aggressive large B cell non-Hodgkin’s lymphoma (NHL) Submit BLA 2H19 Celsion Corp. (NASDAQ:CLSN) / Yakult Honsha Co. Ltd....
BioCentury | May 9, 2018
Distillery Therapeutics

Cancer

...includes Phase I testing of AZD0156 in combination with Camptosar or Lynparza in solid tumors. Yakult Honsha Co. Ltd....
BioCentury | Dec 15, 2017
Clinical News

4SC reports Phase I data for resminostat in pancreatic and biliary tract cancer

...In September, 4SC AG (Xetra:VSC) said partner Yakult Honsha Co. Ltd. (Tokyo:2267) reported data from a Phase I trial...
...Data were presented at the European Society for Medical Oncology meeting in Madrid. 4SC said Yakult...
...Drug designation in the U.S. and EU to treat Hodgkin's lymphoma and hepatocellular cancer (HCC). Yakult...
BioCentury | Dec 7, 2016
Clinical News

ThermoDox: Ph III OPTIMA ongoing

...RFA) vs. RFA alone. The trial has enrolled about 40% of the planned 550 patients. Yakult...
...in 2013 (see BioCentury, Jan. 28, 2013 ). Celsion Corp. (NASDAQ:CLSN; Tel Aviv:CLSN), Lawrenceville, N.J. Yakult Honsha Co. Ltd....
...PFS) Status: Phase III ongoing Milestone: Complete Phase III enrollment (early 2018) Julian Zhu ThermoDox heat-activated liposome Celsion Corp. Yakult Honsha Co. Ltd. Zhejiang...
BioCentury | Oct 17, 2016
Product Development

Yes we PanCAN

...Pharmaceuticals Inc. (NYSE-M:RNN) RX-3117 DNA methyltransferase Ph I/II 4SC AG (Xetra:VSC) / Menarini Group / Yakult Honsha Co. Ltd....
BioCentury | Sep 29, 2016
Distillery Therapeutics

Therapeutics: Nuclear receptor binding protein 2 (NRBP2)

...adjuvant therapy for HCC. Aeterna Zentaris Inc. , Handok Inc. , Hikma Pharmaceuticals plc and Yakult Honsha Co. Ltd....
BioCentury | Dec 7, 2015
Clinical News

Elplat oxaliplatin regulatory update

...colorectal cancer; as postoperative adjuvant chemotherapy for colon cancer; and for curatively unresectable pancreatic carcinoma. Yakult...
...with oxalate and diaminocyclohexane in Japan under a 1997 deal. Debiopharm Group , Lausanne, Switzerland Yakult Honsha Co. Ltd....
BioCentury | Aug 17, 2015
Clinical News

ThermoDox heat-activated liposome: Additional Phase III data

...& June 24, 2013). ThermoDox is in the Phase III OPTIMA trial to treat HCC. Yakult...
...in China and its territories (see BioCentury, Jan. 28, 2013). Celsion Corp. (NASDAQ:CLSN), Lawrenceville, N.J. Yakult Honsha Co. Ltd....
BioCentury | Aug 10, 2015
Clinical News

Resminostat: Phase I started

...24 patients. The second part will test the selected regimen in an additional 20 patients. Yakult...
...Taiho Pharmaceutical Co. Ltd. (Tokyo, Japan) markets Teysuno in Japan. 4SC AG (Xetra:VSC), Planegg-Martinsried, Germany Yakult Honsha Co. Ltd....
BioCentury | Jul 20, 2015
Clinical News

ThermoDox heat-activated liposome: Updated Phase I/II data

...start the European Euro-DIGNITY trial of ThermoDox in patients with recurrent chest wall breast cancer. Yakult...
...in China and its territories (see BioCentury, Jan. 28, 2013). Celsion Corp. (NASDAQ:CLSN), Lawrenceville, N.J. Yakult Honsha Co. Ltd....
Items per page:
1 - 10 of 109